News Provided By
On Demand Pharmaceuticals
January 10, 2025, 09:11 GMT
Rockville, MD, United States, January 10, 2025 – On Demand Pharmaceuticals (ODP), a leader in decentralized pharmaceutical medicine production, celebrates a year of significant milestones in 2024 and unveils strategic objectives for 2025 aimed at further strengthening the domestic pharmaceutical supply chain and mitigating drug shortages.
A Transformative 2024
On Demand Pharmaceuticals experienced a landmark year in 2024, marked by significant leadership changes and progress toward commercial readiness.
New Leadership and a Refined Focus
ODP appointed Matt Pietras as CEO. A seasoned CFO and life sciences executive, Matt brings over two decades of experience leading global finance and operating teams through the clinical and commercial development of both therapeutics and diagnostics. His background spans the full spectrum of life sciences companies—from early-stage private start-ups to large, publicly traded global pharmaceutical organizations, including experience with corporate spin-outs. Throughout his career, Pietras has successfully led private and public capital raises, overseen all facets of finance and accounting, and managed global business operations.
ODP also welcomed Jarrod Borkat as Chief Strategic and Commercial Officer, tapping into his 25 years of leadership in business development, marketing, and corporate strategy. During his tenures at MedImmune, AstraZeneca, and Boehringer Ingelheim, he forged multi-million-dollar partnerships, led pipeline expansions, driven growth of international brands and played a pivotal commercial leadership role in creating a blockbuster drug. His record of guiding initiatives from early-stage innovation to global commercial success positions him to drive ODP’s long-term growth and innovation.
Together, Matt and Jarrod have been instrumental in driving ODP’s commercial strategy and building partnerships that position the company for growth. The ODP executive management team collaborated on the development of a 5-year Strategic Plan focused on improving medication access, eliminating drug shortages, and commercializing their novel platform for on-demand point-of-care production of Medications as a Service™ through their Pharmacy on Demand™ platform
Milestone Achievements
Throughout 2024, ODP accelerated its commercial readiness on multiple fronts. Throughout the first half of the year the company successfully operated a pilot Pharmacy on Demand™ with North Mississippi Health Services (NMHS). This pilot proved ODP’s ability to produce Medications as a Service™ through point-of-care production while upholding the highest quality standards. The company compounded approximately 12,000 prefilled syringes, across a fixed formulary of five medications on the FDA drug shortage list. Upon completion of the pilot, and inspection by the Mississippi Board of Pharmacy, ODP was granted authority to compound medications across an unrestricted formulary under 503A regulations.
In mid-2024 ODP initiated a first-of-its kind project sponsored by the Office of Naval Research intended to demonstrate agile distributed manufacturing of multiple API at its cGMP facility in Rockville, MD followed by finished drug manufacturing in its modular cGMP-compliant Pharmacy on Demand™ at the point-of-care in Tupelo, MS. The successful completion of this project includes both a DMF filing and an ANDA submission to the FDA, further demonstrating the superiority of ODP’s distributed manufacturing platform. This project is expected to proceed through 2026.
The management team finalized the development of its commercial business plan. A model that involves launching a nationwide network of commercially scalable point-of-care Pharmacy on Demand™ (PoD) facilities deploying agile production of Medications as a Service™ (MaaS). Based on the success in Tupelo, NMHS and ODP were invited to present the outcomes of the pilot at the ASHP Midyear conference in December. The team aligned this opportunity with the launch of commercial marketing for PoD based MaaS, generating tremendous interest from hospital pharmacists across the nation.
Strategic Vision for 2025:
Looking ahead to 2025, ODP is committed to three core strategic growth priorities:
- Securing Key Customers – ODP will focus on expanding commercial partnerships, working with NMHS to convert the pilot facility into a cGMP compliant 503B Pharmacy on Demand™ (PoD), and broadening its formulary based on market needs and early adopter feedback. ODP will secure additional Memorandums of Understanding (MOUs) with healthcare partners to further solidify demand.
- Strengthening Capital Resources – ODP will pursue public-private partnerships to fuel strategic growth. In addition, to support commercialization the company will initiate fundraising among private investors and strategic capitalists. These transactions will fuel the expansion of Pharmacy on Demand™ facilities and broaden the adoption of Medications as a Service™. The company will build a domestic network of strategic partnerships with key suppliers to help ensure supply chain resilience and reduce our dependency on foreign manufactured medications.
- Company Growth and Culture – As ODP scales its operations, the company will continue to invest in disciplined growth strategies, with a focus on building a values-driven, principle-guided organizational culture. This includes expanding hiring initiatives, enhancing employee development programs, and fostering an environment that prioritizes quality, integrity, and innovation.
“ODP is committed to reshaping the future of pharmaceutical manufacturing and point of care medication production by addressing critical supply chain vulnerabilities,” said Matt Pietras, CEO of On Demand Pharmaceuticals. “Our 2024 achievements have laid a strong foundation, and we are excited to build on this momentum as we execute our 2025 vision.”
About On Demand Pharmaceuticals
On Demand Pharmaceuticals (ODP) is revolutionizing the pharmaceutical supply chain with its Pharmacy on Demand technology, enabling on-site drug production to mitigate shortages and improve medication access. With a focus on advanced manufacturing, regulatory excellence, and supply chain resilience, ODP is redefining the future of pharmaceuticals.
For more information about On Demand Pharmaceuticals and its innovative solutions, visit www.ondemandpharma.com.
For media inquiries, please contact:
On Demand Pharmaceuticals
301-701-6998
Note: This release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied herein.